CA2932077A1 - Methode pour diagnostiquer des troubles associes a une lesion cerebrale - Google Patents
Methode pour diagnostiquer des troubles associes a une lesion cerebrale Download PDFInfo
- Publication number
- CA2932077A1 CA2932077A1 CA2932077A CA2932077A CA2932077A1 CA 2932077 A1 CA2932077 A1 CA 2932077A1 CA 2932077 A CA2932077 A CA 2932077A CA 2932077 A CA2932077 A CA 2932077A CA 2932077 A1 CA2932077 A1 CA 2932077A1
- Authority
- CA
- Canada
- Prior art keywords
- fabp
- brain damage
- polypeptide
- stroke
- related disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000029028 brain injury Diseases 0.000 title claims abstract description 89
- 230000006931 brain damage Effects 0.000 title claims abstract description 87
- 231100000874 brain damage Toxicity 0.000 title claims abstract description 86
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 82
- 238000002405 diagnostic procedure Methods 0.000 title description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 109
- 229920001184 polypeptide Polymers 0.000 claims abstract description 108
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 105
- 101710163063 Ubiquitin fusion degradation protein 1 homolog Proteins 0.000 claims abstract description 60
- 101710094461 Ubiquitin recognition factor in ER-associated degradation protein 1 Proteins 0.000 claims abstract description 60
- 108010072220 Cyclophilin A Proteins 0.000 claims abstract description 40
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 claims abstract description 40
- 210000001124 body fluid Anatomy 0.000 claims abstract description 38
- 239000010839 body fluid Substances 0.000 claims abstract description 38
- 230000001105 regulatory effect Effects 0.000 claims abstract description 37
- 230000004570 RNA-binding Effects 0.000 claims abstract description 34
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims abstract description 32
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims abstract description 32
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 claims abstract description 30
- 102000048176 Prostaglandin-D synthases Human genes 0.000 claims abstract description 29
- 108030003866 Prostaglandin-D synthases Proteins 0.000 claims abstract description 29
- 102000007456 Peroxiredoxin Human genes 0.000 claims abstract description 27
- 102000007659 Protein Deglycase DJ-1 Human genes 0.000 claims abstract description 27
- 108010032428 Protein Deglycase DJ-1 Proteins 0.000 claims abstract description 27
- 108030002458 peroxiredoxin Proteins 0.000 claims abstract description 27
- 102000003908 Cathepsin D Human genes 0.000 claims abstract description 21
- 108090000258 Cathepsin D Proteins 0.000 claims abstract description 21
- 102100035632 Calcyphosin Human genes 0.000 claims abstract description 20
- 101710085913 Calcyphosin Proteins 0.000 claims abstract description 20
- 102100023206 Neuromodulin Human genes 0.000 claims abstract description 20
- 101710144282 Neuromodulin Proteins 0.000 claims abstract description 20
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 claims abstract description 18
- 101710118908 Fatty acid-binding protein, adipocyte Proteins 0.000 claims abstract description 18
- 102100025038 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Human genes 0.000 claims abstract description 18
- 101710186825 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Proteins 0.000 claims abstract description 18
- 102100030421 Fatty acid-binding protein 5 Human genes 0.000 claims abstract description 17
- 101710083187 Fatty acid-binding protein 5 Proteins 0.000 claims abstract description 17
- -1 Neurofflament L Proteins 0.000 claims abstract description 17
- 239000001177 diphosphate Substances 0.000 claims abstract description 10
- 235000011180 diphosphates Nutrition 0.000 claims abstract description 10
- 239000002777 nucleoside Substances 0.000 claims abstract description 8
- 208000006011 Stroke Diseases 0.000 claims description 104
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 82
- 108010062715 Fatty Acid Binding Protein 3 Proteins 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 63
- 238000003556 assay Methods 0.000 claims description 58
- 102100023252 Nucleoside diphosphate kinase A Human genes 0.000 claims description 50
- 239000000463 material Substances 0.000 claims description 44
- 238000003745 diagnosis Methods 0.000 claims description 42
- 210000002381 plasma Anatomy 0.000 claims description 30
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 27
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 25
- 101100226596 Gallus gallus FABP gene Proteins 0.000 claims description 23
- 238000002965 ELISA Methods 0.000 claims description 22
- 238000001514 detection method Methods 0.000 claims description 22
- 108010081372 NM23 Nucleoside Diphosphate Kinases Proteins 0.000 claims description 20
- 230000004481 post-translational protein modification Effects 0.000 claims description 19
- 102000008763 Neurofilament Proteins Human genes 0.000 claims description 18
- 108010088373 Neurofilament Proteins Proteins 0.000 claims description 18
- 210000005044 neurofilament Anatomy 0.000 claims description 18
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 17
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 15
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 15
- 102100037733 Fatty acid-binding protein, brain Human genes 0.000 claims description 14
- 101710098548 Fatty acid-binding protein, brain Proteins 0.000 claims description 14
- 206010019196 Head injury Diseases 0.000 claims description 14
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 13
- 201000004810 Vascular dementia Diseases 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 12
- 206010018985 Haemorrhage intracranial Diseases 0.000 claims description 11
- 208000008574 Intracranial Hemorrhages Diseases 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- 238000004422 calculation algorithm Methods 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 8
- 230000004988 N-glycosylation Effects 0.000 claims description 5
- 238000004393 prognosis Methods 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 4
- 210000001138 tear Anatomy 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 102100037738 Fatty acid-binding protein, heart Human genes 0.000 claims 13
- 102000005720 Glutathione transferase Human genes 0.000 claims 8
- 108010070675 Glutathione transferase Proteins 0.000 claims 8
- 108010044790 Nucleoside-Phosphate Kinase Proteins 0.000 claims 1
- 102000005811 Nucleoside-phosphate kinase Human genes 0.000 claims 1
- 208000035475 disorder Diseases 0.000 abstract description 45
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract description 26
- 108010024636 Glutathione Proteins 0.000 abstract description 13
- 229960003180 glutathione Drugs 0.000 abstract description 13
- 102000011026 Fatty Acid Binding Protein 3 Human genes 0.000 description 53
- 108090000623 proteins and genes Proteins 0.000 description 41
- 102000004169 proteins and genes Human genes 0.000 description 41
- 235000018102 proteins Nutrition 0.000 description 40
- 239000000499 gel Substances 0.000 description 35
- 102100038833 Ubiquitin recognition factor in ER-associated degradation protein 1 Human genes 0.000 description 34
- 239000000523 sample Substances 0.000 description 34
- 238000012549 training Methods 0.000 description 31
- 101710149890 Nucleoside diphosphate kinase A Proteins 0.000 description 30
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 29
- 239000000090 biomarker Substances 0.000 description 24
- 230000035945 sensitivity Effects 0.000 description 18
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 15
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 15
- 102000013394 Troponin I Human genes 0.000 description 15
- 108010065729 Troponin I Proteins 0.000 description 15
- 239000003550 marker Substances 0.000 description 14
- 101000573172 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Nucleoside diphosphate kinase Proteins 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 238000005259 measurement Methods 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 9
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 239000013024 dilution buffer Substances 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 6
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000000302 ischemic effect Effects 0.000 description 5
- 208000015122 neurodegenerative disease Diseases 0.000 description 5
- 230000000926 neurological effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- 108091006629 SLC13A2 Proteins 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- 206010000891 acute myocardial infarction Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002008 hemorrhagic effect Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 229910052709 silver Inorganic materials 0.000 description 4
- 239000004332 silver Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 101710159080 Aconitate hydratase A Proteins 0.000 description 3
- 101710159078 Aconitate hydratase B Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 102000019298 Lipocalin Human genes 0.000 description 3
- 108050006654 Lipocalin Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 3
- 101710105008 RNA-binding protein Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 229960003624 creatine Drugs 0.000 description 3
- 239000006046 creatine Substances 0.000 description 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000007971 neurological deficit Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- 235000011330 Armoracia rusticana Nutrition 0.000 description 2
- 240000003291 Armoracia rusticana Species 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 208000004552 Lacunar Stroke Diseases 0.000 description 2
- 102000047918 Myelin Basic Human genes 0.000 description 2
- 101710107068 Myelin basic protein Proteins 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 208000024777 Prion disease Diseases 0.000 description 2
- 102000013674 S-100 Human genes 0.000 description 2
- 108700021018 S100 Proteins 0.000 description 2
- 101100226329 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) EXO84 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710179452 Ubiquitin fusion degradation protein 1 Proteins 0.000 description 2
- BTKMJKKKZATLBU-UHFFFAOYSA-N [2-(1,3-benzothiazol-2-yl)-1,3-benzothiazol-6-yl] dihydrogen phosphate Chemical compound C1=CC=C2SC(C3=NC4=CC=C(C=C4S3)OP(O)(=O)O)=NC2=C1 BTKMJKKKZATLBU-UHFFFAOYSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 230000003683 cardiac damage Effects 0.000 description 2
- 230000008809 cell oxidative stress Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002565 electrocardiography Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000009593 lumbar puncture Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- HKJKONMZMPUGHJ-UHFFFAOYSA-N 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 HKJKONMZMPUGHJ-UHFFFAOYSA-N 0.000 description 1
- VSMDINRNYYEDRN-UHFFFAOYSA-N 4-iodophenol Chemical compound OC1=CC=C(I)C=C1 VSMDINRNYYEDRN-UHFFFAOYSA-N 0.000 description 1
- ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
- 206010052075 Acquired epileptic aphasia Diseases 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 208000034577 Benign intracranial hypertension Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006145 Brain stem haemorrhage Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000003813 Cis-trans-isomerases Human genes 0.000 description 1
- 108090000175 Cis-trans-isomerases Proteins 0.000 description 1
- 201000003863 Dandy-Walker Syndrome Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 1
- 102000002140 Fatty Acid-Binding Protein 7 Human genes 0.000 description 1
- 108010001387 Fatty Acid-Binding Protein 7 Proteins 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 201000005802 Landau-Kleffner Syndrome Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 238000012896 Statistical algorithm Methods 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 description 1
- 206010042928 Syringomyelia Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100032947 UMP-CMP kinase 2, mitochondrial Human genes 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000021235 carbamoylation Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000011496 digital image analysis Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 108091022862 fatty acid binding Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000000955 peptide mass fingerprinting Methods 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 208000001381 pseudotumor cerebri Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 238000011309 routine diagnosis Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 208000012720 thalamic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0322063.9 | 2003-09-20 | ||
| GBGB0322063.9A GB0322063D0 (en) | 2003-09-20 | 2003-09-20 | Diagnostic method for brain damage-related disorders |
| GB0414089.3 | 2004-06-23 | ||
| GBGB0414089.3A GB0414089D0 (en) | 2003-09-20 | 2004-06-23 | Diagnostic method for brain damage-related disorders |
| GB0419068A GB0419068D0 (en) | 2003-09-20 | 2004-08-27 | Diagnostic method for brain damage-related disorders |
| GB0419068.2 | 2004-08-27 | ||
| CA2532130A CA2532130C (fr) | 2003-09-20 | 2004-09-20 | Methode pour diagnostiquer des troubles associes a une lesion cerebrale |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2532130A Division CA2532130C (fr) | 2003-09-20 | 2004-09-20 | Methode pour diagnostiquer des troubles associes a une lesion cerebrale |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2932077A1 true CA2932077A1 (fr) | 2005-03-31 |
| CA2932077C CA2932077C (fr) | 2020-06-02 |
Family
ID=29266361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2932077A Active CA2932077C (fr) | 2003-09-20 | 2004-09-20 | Methode pour diagnostiquer des troubles associes a une lesion cerebrale |
Country Status (4)
| Country | Link |
|---|---|
| CA (1) | CA2932077C (fr) |
| DK (1) | DK1664795T3 (fr) |
| ES (3) | ES2657320T3 (fr) |
| GB (2) | GB0322063D0 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109696549A (zh) * | 2017-10-20 | 2019-04-30 | 成都蓝瑙生物技术有限公司 | 用于脑中风的发光elisa体外诊断试剂盒 |
| EP4235181A3 (fr) * | 2008-08-11 | 2024-02-28 | Banyan Biomarkers Inc | Procédé de détection de biomarqueur et dosage d'état neurologique |
-
2003
- 2003-09-20 GB GBGB0322063.9A patent/GB0322063D0/en not_active Ceased
-
2004
- 2004-06-23 GB GBGB0414089.3A patent/GB0414089D0/en not_active Ceased
- 2004-09-20 ES ES04787496.1T patent/ES2657320T3/es active Active
- 2004-09-20 ES ES10181193.3T patent/ES2657442T3/es active Active
- 2004-09-20 DK DK04787496.1T patent/DK1664795T3/en active
- 2004-09-20 CA CA2932077A patent/CA2932077C/fr active Active
- 2004-09-20 ES ES10181407.7T patent/ES2657422T3/es active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4235181A3 (fr) * | 2008-08-11 | 2024-02-28 | Banyan Biomarkers Inc | Procédé de détection de biomarqueur et dosage d'état neurologique |
| CN109696549A (zh) * | 2017-10-20 | 2019-04-30 | 成都蓝瑙生物技术有限公司 | 用于脑中风的发光elisa体外诊断试剂盒 |
| CN109696549B (zh) * | 2017-10-20 | 2022-11-01 | 成都蓝瑙生物技术有限公司 | 用于脑中风的发光elisa体外诊断试剂盒 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2657442T3 (es) | 2018-03-05 |
| CA2932077C (fr) | 2020-06-02 |
| GB0414089D0 (en) | 2004-07-28 |
| ES2657320T3 (es) | 2018-03-02 |
| DK1664795T3 (en) | 2018-02-12 |
| GB0322063D0 (en) | 2003-10-22 |
| ES2657422T3 (es) | 2018-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7955804B2 (en) | Diagnostic method for brain damage-related disorders | |
| JP5281397B2 (ja) | 脳損傷関連障害の診断法 | |
| JP5775568B2 (ja) | 診断方法 | |
| DK2389587T3 (en) | Diagnostic and prognostic methods related Alzheimer's Disease | |
| AU2004264560B2 (en) | Method for discriminating between ischemic and haemorrhagic stroke | |
| KR100689995B1 (ko) | 알돌라제를 포함하는 망막혈관 질환 진단용 조성물 및 그진단방법 | |
| CA2932077C (fr) | Methode pour diagnostiquer des troubles associes a une lesion cerebrale | |
| EP3242134A1 (fr) | Dosage pour le diagnostic d'une maladie neurologique | |
| US20090042211A1 (en) | Method for the Selective Detection of Pathological Protein Depositions | |
| US20140309133A1 (en) | Novel Method for Diagnosis of High-Affinity Binders and Marker Sequences | |
| US20060269963A1 (en) | Composition for the diagnosis of retinal vascular disease comprising aldolase and method for diagnosis using it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160603 |